

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

ANNOUNCEMENT ON THE FIRST SHARE REPURCHASE AND THE COMPLETION OF THE SHARE REPURCHASE PLAN

Reference is made to the announcements of RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司) (the “**Company**”) dated December 15, 2025 and January 15, 2026 (the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

I. INFORMATION REGARDING THE SHARE REPURCHASE PLAN

The Company convened the Thirty-second Meeting of the Second Session of the Board of Directors on December 15, 2025, reviewed and approved the Resolution on the Plan for Repurchasing the Company’s Shares by Way of Centralized Bidding. It was agreed that the Company shall use its own funds and/or self-raised funds to repurchase part of the Company’s issued RMB-denominated ordinary shares (A-shares) by way of centralized bidding. The total amount of funds proposed for the repurchase shall be not less than RMB20 million (inclusive) and not more than RMB40 million (inclusive). The repurchased shares will be used for an employee stock ownership plan or equity incentive at an appropriate time in the future. The repurchase price shall not exceed RMB95 per share (inclusive). The repurchase period shall be 12 months from the date the Company’s Board of Directors reviewed and approved this repurchase plan.

The Company convened the Thirty-fifth Meeting of the Second Session of the Board of Directors on January 15, 2026, reviewed and approved the Resolution on Adjusting the Upper Limit of the Share Repurchase Price. It was agreed that the Company shall adjust the upper limit of the share repurchase price from no more than RMB95 per share (inclusive) to no more than RMB116 per share (inclusive), and the adjusted repurchase price shall not be higher than 150% of the average trading price of the Company's shares in the 30 trading days before the Board of Directors reviewed and approved the Resolution on Adjusting the Upper Limit of the Share Repurchase Price. Except for the adjustment of the upper limit of the repurchase price, the other contents of this repurchase plan remain unchanged. This adjustment is based on the confidence in the Company's sustainable and stable development in the future and the recognition of the Company's value, and the decision is made taking into account the changes in the securities market and the progress of share repurchases.

II. IMPLEMENTATION OF REPURCHASE

On January 20, 2026, the Company repurchased 194,144 shares of the Company for the first time through the trading system of the Shanghai Stock Exchange through centralized bidding transactions, accounting for 0.0344% of the Company's total share capital of 563,710,243 shares, the highest price of the repurchase transaction was RMB103.78 per share, the lowest price was RMB102.17 per share, and the total amount of funds paid was RMB20,004,012.12 (excluding transaction fees).

As of January 20, 2026, the Company has repurchased a total of 194,144 shares of the Company through centralized bidding transactions through the trading system of the Shanghai Stock Exchange, accounting for 0.0344% of the Company's total share capital, with the highest price of RMB103.78 per share and the lowest price of RMB102.17 per share of the repurchase transaction, and the total amount of funds paid is RMB20,004,012.12 (excluding transaction fees). The Company's share repurchase has reached the lower limit of the total repurchase funds and has not exceeded the upper limit of the total repurchase funds, and the implementation of the repurchase plan has been completed.

In the process of this share repurchase, the Company repurchased the Company's shares in strict accordance with relevant laws and regulations, in accordance with the Rules on Share Repurchases by Listed Companies, the Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 – Share Repurchases and other relevant regulations and the Company's share repurchase plan. There is no difference between the actual implementation of the repurchase plan and the originally disclosed repurchase plan, and the Company has completed the repurchase in accordance with the disclosed plan.

The funds used for the implementation of the share repurchase are the Company's own funds and/or self-raised funds, which will not have a significant impact on the Company's business activities, financial situation and future development. This share repurchase will not lead to a change in the Company's control, and the Company's equity distribution after the repurchase meets the conditions of a listed company and will not affect the Company's listing status.

III. THE TRADING OF SHARES BY RELEVANT ENTITIES DURING THE REPURCHASE PERIOD

On December 16, 2025, the Company disclosed the share repurchase plan for the first time, as detailed in the *Plan of RemeGen Co., Ltd. on Share Repurchase by Way of Centralized Bidding* (Announcement No.: 2025-055) disclosed by the Company on the website of the Shanghai Stock Exchange. After verification, from the date of the Company's first disclosure of the share repurchase plan to the day before the disclosure of this Announcement, the Company's Directors, senior management, controlling shareholders, actual controllers and persons acting in concert did not directly purchase or sell the Company's A shares.

IV. STATEMENT OF CHANGES IN SHARES

Before and after this share repurchase, the Company's shares changed as follows:

| Share Class | Before the Repurchase | | After the Repurchase | |
|--|---------------------------|-----------------------|---------------------------|-----------------------|
| | Number of Shares (Shares) | Proportion (%) | Number of Shares (Shares) | Proportion (%) |
| Tradable Shares with Restrictions | 192,803,132 | 34.20% | 192,803,132 | 34.20% |
| Tradable Shares without Restrictions | 370,907,111 | 65.80% | 370,907,111 | 65.80% |
| – Among which: Special Securities Account for Repurchase | 0 | 0% | 194,144 | 0.03% |
| Total Shares | <u>563,710,243</u> | <u>100.00%</u> | <u>563,710,243</u> | <u>100.00%</u> |

V. ARRANGEMENTS FOR THE HANDING OF REPURCHASED SHARES

The Company has repurchased a total of 194,144 shares, all of which are currently deposited in the special securities account opened by the Company and will be used for the Company's employee stock ownership plans or equity incentive programs at an appropriate time in the future. In the event that the Company fails to utilize all the repurchased shares within three years from the date of announcing the completion of the share repurchase implementation, the unused repurchased shares shall be cancelled. During the period when the aforementioned repurchased shares are deposited in the Company's special securities account for repurchase, such shares shall not be entitled to the rights of voting at shareholders' meetings, profit distribution, conversion of provident funds into share capital, subscription for new shares, share allotment, pledge, or other relevant rights. Going forward, the Company will strictly comply with the Rules on Share Repurchases by Listed Companies, the Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 – Share Repurchases, and other applicable laws and regulations, as well as the Company's share repurchase plan. The Company will select an appropriate time to utilize the repurchased shares based on market conditions and promptly fulfill its information disclosure obligations.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, The People's Republic of China
January 20, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* *For identification purpose only*